Recombinant therapeutic proteins produced using ProCellEx®, plant cell-based protein expression system. Lead asset, PRX-102, modified version of recombinant human alpha-GAL-A protein, in multiple Ph 3 trials for Fabry disease, partnered globally w Chiesi - Interim Ph 3 (PRX-102) data demonstrated improvement in kidney function in pts switched from Replagal® to PRX-102. OPRX-106 is in Ph 2 development for ulcerative colitis and PRX-110 (alidornase alfa) is in Ph 2 development for Cystic Fibrosis.
Marketed, Phase III
Autoimmune, Gastrointestinal, Rare Disease
2 Snunit Street, Science Park
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by